Original Article

Sleep and cognitive performance: cross-sectional associations in the UK Biobank

Simon D. Kylea,*, Claire E. Sextonb, Bernd Feigec, Annemarie I. Luika, Jacqueline Laned, Richa Saxenad, Simon G. Andersonh, David A. Bechtoldi, William Dixonj, Max A. Littlek, l, David Raym, Dieter Riemann c, Colin A. Espiea, Martin K. Rutter m, n, Kai Spiegelhalder c

a Sleep and Circadian Neuroscience Institute (SCNi), Nuffield Department of Clinical Neurosciences, University of Oxford, UK
b FMRIB Centre, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK
c Clinic for Psychiatry and Psychotherapy, Medical Centre – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
d Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA
e Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
f Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA
g Department of Anesthesia, Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA, USA
h Cardiovascular Research Group, Institute of Cardiovascular Sciences, The University of Manchester, Manchester, UK
i Faculty of Life Sciences, University of Manchester, Manchester, UK
j Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
k Engineering and Applied Science, Aston University, Birmingham, UK
l Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA
m Centre for Endocrinology and Diabetes, Institute of Human Development, University of Manchester, UK
n Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

Article info

Article history:
Received 20 December 2016
Received in revised form 1 June 2017
Accepted 1 July 2017
Available online 14 July 2017

Keywords:
Insomnia
Cognitive performance
Chronotype
Sleep duration
Sleep medication

Abstract

Objective: The relationship between insomnia symptoms and cognitive performance is unclear, particularly at the population level. We conducted the largest examination of this association to date through analysis of the UK Biobank, a large population-based sample of adults aged 40–69 years. We also sought to determine associations between cognitive performance and self-reported chronotype, sleep medication use and sleep duration.

Methods: This cross-sectional, population-based study involved 477,529 participants, comprising 133,314 patients with frequent insomnia symptoms (age: 57.4 ± 7.7 years; 62.1% female) and 344,215 controls without insomnia symptoms (age: 56.1 ± 8.2 years; 52.0% female). Cognitive performance was assessed by a touchscreen test battery probing reasoning, basic reaction time, numeric memory, visual memory, and prospective memory. Adjusted models included relevant demographic, clinical, and sleep variables.

Results: Frequent insomnia symptoms were associated with cognitive impairment in unadjusted models; however, these effects were reversed after full adjustment, leaving those with frequent insomnia symptoms showing statistically better cognitive performance over those without. Relative to intermediate chronotype, evening chronotype was associated with superior task performance, while morning chronotype was associated with the poorest performance. Sleep medication use and both long (>9 h) and short (<7 h) sleep durations were associated with impaired performance.

Conclusions: Our results suggest that after adjustment for potential confounding variables, frequent insomnia symptoms may be associated with a small statistical advantage, which is unlikely to be clinically meaningful, on simple neurocognitive tasks. Further work is required to examine the mechanistic underpinnings of an apparent evening chronotype advantage in cognitive performance and the impairment associated with morning chronotype, sleep medication use, and sleep duration extremes.

© 2017 Elsevier B.V. All rights reserved.
1. Introduction

Insomnia is defined as persistent difficulties with sleep initiation and/or maintenance, resulting in significant impairment to daytime functioning. At the symptom level, insomnia affects up to one-third of the adult population, while persistent insomnia affects approximately 10–12% and is associated with increased risk for cardiovascular disease, depression, and early mortality [1,2]. Both daytime functioning and quality of life are known to be severely affected in those with insomnia and often drive treatment seeking [3–5]. More specifically, previous work shows that the most commonly cited areas of daytime dysfunction are problems with fatigue, work performance, cognitive performance, and emotion regulation [6]. Insomnia has also been associated with a range of serious and non-serious sleep-related accidents [7].

While experimental sleep loss engenders reliable cognitive impairment, particularly for vigilance, complex attention, and working memory [8], there has been comparatively little work on insomnia. In general, the field has been characterised by mixed findings, with some studies showing impairment and others failing to observe differences from controls [9]. Nevertheless, meta-analytic data suggest that patients exhibit reliable impairments in tasks probing episodic memory, working memory, and problem solving, with small-to-medium effect sizes [10]. Recent, well-controlled studies have found evidence of insomnia-related impairments in switching of attention and working memory [11], and sustained attention and episodic memory [12]. However, there continues to be conflicting findings in the insomnia literature [13–15], and studies generally recruit small samples of patients with ‘primary insomnia’, who are otherwise healthy.

Larger epidemiology-based studies of insomnia symptoms and cognitive performance similarly display mixed results: showing evidence of impairment [16], no evidence of impairment [17] or impairment only for specific insomnia sub-groups [15,18]. To our knowledge, no study has investigated insomnia symptoms and cognitive performance in a large population-based sample of middle-aged adults, with a standardised test battery, while simultaneously appraising the effects of other important sleep variables, including chronotype, sleep duration, and sleep medication.

The present study aimed to conduct the largest investigation of insomnia symptoms and cognitive performance to date through analysis of UK Biobank data. The UK Biobank is a large population-based study of >500,000 adults aged between 40 and 69 years, providing a unique opportunity to assess associations in groups of poor and good sleepers and to adequately control for the influence of several potential confounding variables. We hypothesised that insomnia would be independently associated with impairments in all measures of cognition (reasoning, basic reaction time, numeric memory, visual memory, and prospective memory) after controlling for potential confounding variables. As a secondary aim, we examined associations between cognitive performance and chronotype, sleep medication use and self-reported sleep duration.

2. Methods

2.1. Participants

Details of the UK Biobank are available elsewhere [19]. In brief, adults aged 40–69 years who were registered with the UK National Health Service and living within 25 miles of a study assessment centre were invited to participate. Approximately nine million invitations led to a final sample of 501,718 participants. For the purposes of the present study, participants were excluded if they self-reported a neurological condition (eg, neurodegenerative disease, stroke, head injury or epilepsy; n = 22,065), had a diagnosis of sleep-disordered breathing (n = 1511) or had incomplete data for insomnia symptoms (n = 613), leaving a total of 477,529 participants. Twenty-eight percent of the sample reported frequent insomnia symptoms (n = 133,314; mean age = 57.4 years, SD = 7.7 years; 62.1% female), while the remaining 72% of participants made up the comparison group (n = 344,215; mean age = 56.1 years, SD = 8.2 years; 52.0% female). This comparison group was composed of those reporting insomnia symptoms ‘sometimes’ [48%] and ‘never/rarely’ [28%].

2.2. Procedure and measurements

All the procedures performed in the UK Biobank research were approved by the NHS National Research Ethics Service (Ref. 11/NW/0382). All participants gave written informed consent. Assessments were conducted at 22 centres across England, Scotland, and Wales between 2006 and 2010. Questionnaires and cognitive assessments were administered in a standardised order using a computerised touchscreen interface, followed by a face-to-face interview with a research nurse to obtain additional data. Sleep-related variables and cognitive performance were assessed in a single visit that lasted approximately 90 min.

2.3. Sleep-related variables

To assess insomnia symptoms, participants were asked ‘Do you have trouble falling asleep at night or do you wake up in the middle of the night?’ with responses ‘never/rarely’, ‘sometimes’ and ‘usually’. Participants were categorised as having frequent insomnia symptoms if they answered ‘usually’ to this question, while the remaining participants made up the control group without frequent insomnia symptoms. Chronotype was assessed using the following question: ‘Do you consider yourself to be’:... ‘definitely a “morning” person’, ‘more a “morning” than “evening” person’, ‘more an “evening” than “morning” person’, ‘definitely an “evening” person’. For the purposes of the present study, we collapsed the two middle responses into an ‘intermediate’ chronotype category, permitting comparisons with the ‘definitely morning’ and ‘definitely evening’ groups. Sleep duration was recorded as the number of reported hours to the following question: ‘About how many hours do you get in every 24 h? (include naps)’. Given previously established U-shape relationships with health and cognition [20], we categorised sleep duration into short (<7 h), normal (7–9 h) and long (>9 h) based on recent guidelines [21].

2.4. Cognitive performance

Five cognitive measures were administered through a computerised touchscreen interface [22]. Time to complete all five cognitive tests was approximately 15 min. The tests were designed specifically for the UK Biobank to allow administration at scale without examiner supervision. The tasks show evidence of an underlying performance factor and good stability over time, with the exception of visual memory performance, which has a comparatively lower intraclass correlation coefficient [22].
The five tasks involved the following instructions:

- **Reasoning**: This task assessed the ability to solve 13 verbal and numeric reasoning problems. Each problem had five possible response options. The dependent variable was the total number of correct answers given (range 0–13) within a 2-min period, with higher scores indicating better performance.

- **Basic reaction time**: This task was delivered in the style of the card game, ‘snap’, and requested respondents to respond with a button press when they detected the appearance of a matching pair of symbols. The dependent variable was the mean response time in milliseconds across 12 matching-pair trials. RT values were log-transformed because of skewed distribution (In x).

- **Numeric short-term memory**: In this task, a string of numbers was presented on the screen, which subsequently disappeared. Participants were then asked to enter the number string from memory, in the reverse order, through a keypad. The dependent variable was the maximum string length recalled correctly (range: 0–12), with higher scores indicating better performance. The test was discontinued after five successive incorrect responses at string length = 2.

- **Visual memory**: In this task, six card pairs of symbols were presented on-screen in a random pattern. Cards were then turned face down on the screen, and participants were asked to locate as many symbol pairs as possible in as few attempts as possible. The dependent variable was the number of errors made during pairs matching (range 0–146), which was log-transformed because of skewed distribution and zero inflation (In (x + 1)).

- **Prospective memory**: In this task, participants were asked to remember to perform a pre-planned instruction. Specifically, at the beginning of the test battery, they were presented with the following instruction: ‘At the end of the games we will show you four coloured symbols and ask you to touch the blue square. However, to test your memory, we want you to actually touch the orange circle instead’. If participants remembered to touch the orange circle on first attempt, they were coded as ‘correct’ (1), while those failing to do so were set to 0.

### 2.5. Demographic data

Demographic data included age, sex, and neighbourhood-level socioeconomic status as measured by the Townsend index of material deprivation. For statistical analyses, socioeconomic status was log-transformed because of skewed distribution by using an ‘ln (x + 7)’ equation (minimum of non-transformed index: −6.26).

Educational qualifications were recorded and were dichotomised according to whether participants held a college/university degree. We also included body mass index (BMI) as a covariate in adjusted analyses.

### 2.6. Medication and clinical data

Current medications were self-reported to the research nurse, and the participants were dichotomised according to whether they were taking sleep medication (sedatives and hypnotics), any other psychotropic medication (mood stabilisers, antidepressants, and antipsychotics) or antihypertensive medication (ACE inhibitors, angiotensin II antagonists, beta blockers, calcium channel blockers, and diuretics). Current depressive symptoms were assessed using the following question: ‘Over the past two weeks, how often have you felt down, depressed or hopeless?’, with the following response options: ‘not at all’, ‘several days’, ‘more than half the days’ or ‘nearly every day’. For the purpose of the present analyses, those scoring ‘several days’, ‘more than half the days’ or ‘nearly every day’ were coded in the ‘depressive symptoms’ category, while those scoring ‘not at all’ were considered in the ‘no depressive symptoms’ category. In addition, participants were dichotomised according to whether they reported hypertension or any cardiovascular disease.

### 2.7. Analyses

Descriptive data presentation included mean values and standard deviations and the proportion of the sample reporting specific questionnaire response options. Questionnaire response options, ‘do not know’ or ‘prefer not to answer’, were handled as missing values. For cognitive dependent variables, the sample size varied across tests because the reasoning and prospective memory tests were added after the commencement of data collection, while the numeric memory task was included from the outset but subsequently removed because of time constraints.

In a first step (unadjusted analyses, model 1), the association between insomnia status (those with frequent insomnia symptoms vs. those without frequent insomnia symptoms) and cognitive performance was analysed using four linear models, with insomnia status as the single predictor variable and reasoning, basic reaction time, numeric memory, and visual memory as dependent variables. The association between insomnia status and prospective memory performance was investigated using a logistic model. In a second step (model 2), age, sex, socioeconomic status, and education were added as covariates in the logistic models described in model 1. In a third step (model 3), chronotype (with the intermediate type as the reference category), sleep medication use, BMI as a continuous variable, hypertension, antihypertensive medication, cardiovascular disease, depressive symptoms, and psychotropic medication were added as further covariates. In a final step (model 4), sleep duration (with 7–9 h as the reference category) was inserted as an additional predictor of cognitive performance. We therefore report unadjusted and multivariate-adjus trations between insomnia status and cognitive outcomes. For chronotype, sleep duration and sleep medication, we report only the fully adjusted relationships (model 4) controlling for all demographic, clinical and remaining sleep variables. Given that we analysed five cognitive tests, the alpha level was set at $p < 0.01$ for all analyses.

### 3. Results

#### 3.1. Sample description

Sociodemographic data for the sample are presented in Table 1. Those with frequent insomnia symptoms were older and more likely to be female, reported shorter sleep duration, were more likely to report using sleep medication, were less likely to hold a university or college degree, were from a lower socioeconomic background, had a higher BMI, were more likely to report hypertension, use of antihypertensive medication or cardiovascular disease, were more likely to report recent depressive symptoms and were more likely to report taking psychotropic medication (all $p < 0.001$).

#### 3.2. Association between insomnia symptoms and cognitive performance

Results from statistical models are presented in Table 2. In unadjusted analyses (model 1), frequent insomnia symptoms were associated with worse performance on the reasoning test, basic reaction time test, numeric memory test and visual memory test. No statistically significant association was observed between
Table 1
Sociodemographic and clinical data of the study sample. Groups differed significantly for all variables (p < 0.001).

<table>
<thead>
<tr>
<th></th>
<th>Sub-group with frequent insomnia symptoms</th>
<th>Sub-group without frequent insomnia symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>133,314</td>
<td>344,215</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.4 ± 7.3</td>
<td>56.1 ± 8.2</td>
</tr>
<tr>
<td>Sex (%) female</td>
<td>62.1%</td>
<td>52.0%</td>
</tr>
<tr>
<td>Sleep duration (h)</td>
<td>6.7 ± 1.3</td>
<td>7.3 ± 1.0</td>
</tr>
<tr>
<td>Sleep medication (%)</td>
<td>2.1%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Education (% with university/college degree)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status(^a)</td>
<td>−1.16 ± 3.16</td>
<td>−1.39 ± 3.04</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>27.8 ± 5.1</td>
<td>27.2 ± 4.6</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>29.9%</td>
<td>23.8%</td>
</tr>
<tr>
<td>Antihypertensive medication (%)</td>
<td>25.4%</td>
<td>19.8%</td>
</tr>
<tr>
<td>Cardiovascular disease (%)</td>
<td>11.0%</td>
<td>7.9%</td>
</tr>
<tr>
<td>Depressive symptoms (%)</td>
<td>34.5%</td>
<td>19.1%</td>
</tr>
<tr>
<td>Psychotropic medication (%)</td>
<td>11.0%</td>
<td>5.8%</td>
</tr>
</tbody>
</table>

BMI: body mass index.
\(^a\) Townsend Index of Material Deprivation.

Table 2
Unadjusted and multivariate-adjusted relationships between insomnia status and cognitive performance. \(\beta\) values indicate unadjusted (model 1) and adjusted (models 2, 3 and 4) group differences between those with frequent insomnia symptoms and those without frequent insomnia symptoms.

<table>
<thead>
<tr>
<th>Cognitive domain</th>
<th>Model 1(^b)</th>
<th>Model 2(^b)</th>
<th>Model 3(^c)</th>
<th>Model 4(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reasoning</td>
<td>(\beta = -1.2 \times 10^{-3}) (n = 158,180)</td>
<td>(\beta = -1.9 \times 10^{-2}) (n = 134,295)</td>
<td>(\beta = -5.9 \times 10^{-2}) (n = 115,935)</td>
<td>(\beta = -9.5 \times 10^{-2}) (n = 115,668)</td>
</tr>
<tr>
<td>Reaction time</td>
<td>(\beta = -1.4 \times 10^{-3}) (n = 473,144)</td>
<td>(\beta = -2.2 \times 10^{-3}) (n = 386,588)</td>
<td>(\beta = -5.9 \times 10^{-3}) (n = 333,095)</td>
<td>(\beta = -6.7 \times 10^{-3}) (n = 332,303)</td>
</tr>
<tr>
<td>Numeric memory</td>
<td>(\beta = -1.0 \times 10^{-3}) (n = 48,091)</td>
<td>(\beta = -1.8 \times 10^{-3}) (n = 40,151)</td>
<td>(\beta = -4.9 \times 10^{-4}) (n = 34,844)</td>
<td>(\beta = -1.6 \times 10^{-4}) (n = 34,753)</td>
</tr>
<tr>
<td>Visual memory</td>
<td>(\beta = -1.4 \times 10^{-3}) (n = 473,955)</td>
<td>(\beta = -9.0 \times 10^{-3}) (n = 372,318)</td>
<td>(\beta = -1.3 \times 10^{-3}) (n = 334,779)</td>
<td>(\beta = -1.4 \times 10^{-3}) (n = 333,966)</td>
</tr>
<tr>
<td>Prospective memory</td>
<td>(\beta = -2.7 \times 10^{-3}) (n = 163,077)</td>
<td>(\beta = -6.1 \times 10^{-3}) (n = 136,770)</td>
<td>(\beta = -1.1 \times 10^{-3}) (n = 117,721)</td>
<td>(\beta = -1.5 \times 10^{-3}) (n = 117,438)</td>
</tr>
</tbody>
</table>

\(^p < 0.01; ^*p < 0.001; ^**p < 0.0001.
\(^a\) Unadjusted analyses.
\(^b\) Adjusted for age, sex, socioeconomic status and education.
\(^c\) Adjusted for age, sex, socioeconomic status, education, BMI, hypertension, cardiovascular disease, antihypertensive medication, depressive symptoms, psychotropic medication, sleep medication, chronotype.
\(^d\) Adjusted for model 3 variables plus sleep duration.

morning chronotype, relative to intermediate chronotype, was associated with poorer performance on the reasoning test, basic reaction time test, numeric memory test, visual memory test, and prospective memory test. Sleep medication use was associated with reduced performance on the reasoning test, basic reaction time test, and prospective memory test but not on the numeric memory test or visual memory test.

73.7% of the sample reported sleep duration between 7 and 9 h, 24.6% reported sleep duration < 7 h, while 1.7% reported sleep duration > 9 h. Both short (< 7 h) and long (> 9 h) sleep durations were associated with poorer performance on the reasoning test, basic reaction time test, numeric memory test, visual memory test, and prospective memory test.

4. Discussion

The principal aim of the present study was to examine cross-sectional associations between insomnia symptoms and cognitive performance in a large population-based sample. We also sought to assess relationships between cognitive performance and sleep duration, chronotype and sleep medication use. Prevalence, demographic and comorbidity profiles of those with insomnia symptoms were consistent with those in previous epidemiological investigations [1]. Unadjusted analyses revealed that those with frequent insomnia symptoms displayed impairment across all cognitive tasks (except prospective memory); however, intermediate adjustment for demographic variables rendered these associations non-significant or reversed their direction. Full adjustment (model 4) for demographic, medical and sleep-related variables left those with frequent insomnia symptoms with a small but statistically significant advantage over those without insomnia for all cognitive measures (except numeric memory). However, sleep medication use and both long (> 9 h) and short (< 7 h) sleep durations were independently associated with cognitive impairment, while evening chronotype was associated with better task performance.

Our study represents the largest investigation of insomnia symptoms and cognitive performance to date, and the results are consistent with those from population-based studies, which similarly failed to observe negative relationships [15,17], while conflicting with others [16,23]. Clearly, our study is unique because of its large sample size and ability to control for the effects of multiple confounding sleep and non-sleep variables. The small but statistically significant advantage of those with insomnia versus those without was unexpected and is unlikely to be clinically meaningful [note, effect size differences in SD units = 0.044 (reasoning), 0.035 (reaction time) and 0.022 (visual memory)]. Nevertheless, it is worth reflecting on what factors may contribute to these consistent
effects. Typical of large epidemiological-based studies, there remains the possibility of unmeasured confounding that may explain group differences. We note that a recent report on the UK Biobank data similarly found, unexpectedly, that those with a history of probable single episode depression or probable recurrent depression displayed a small but statistically significant cognitive advantage over controls [24]. It is possible that our samples are overlapping.

There may also be trait factors relevant to poor sleepers that aid compensation and/or performance facilitation. For example, hyperarousal across cognitive, emotional and neurophysiological levels is characteristic of insomnia [25] and has been suggested to support cognitive performance on relatively brief tasks with low cognitive load [26]. At least two studies have observed quicker reaction times on basic vigilance tasks in insomnia patients relative to controls [27,28]. Hyperarousal has in turn been proposed to hinder performance on more cognitively challenging tasks [29,30], and it may be that tests used in the present study were not of sufficient sensitivity and/or complexity to unmask insomnia-related impairment [31].

Another possibility is that unmeasured personality traits known to be associated with insomnia may contribute to enhanced cognitive performance. We and others have shown that those with insomnia often display high levels of perfectionism, captured through questionnaire and behavioural measures [32–36]. Preliminary work suggests that high levels of perfectionism may confer advantage on specific task-dependent variables under certain conditions [37]. However, studies have also revealed that perfectionistic traits (and associated processes, such as rumination) may be obstructive to task performance [38]. Thus, the drivers behind the observed statistical advantage remain speculative and unclear but could involve both etiological and methodological factors. Of note, supplementary analysis (see Supplementary Table 1) comparing those reporting insomnia symptoms ‘sometimes’ with those reporting insomnia symptoms ‘never/rarely’ did not reveal group differences in adjusted models. However, consistent with the results presented above, those with frequent insomnia symptoms performed better than those reporting insomnia symptoms ‘never/rarely’. There is, therefore, no clear dose–response effect between frequency of insomnia symptoms and cognitive performance.

4.1. Chronotype, sleep medication and sleep duration

While sleep disturbance was not independently associated with task impairment, we observed associations between cognitive performance and chronotype, sleep medication use and sleep duration. Evening chronotype was associated with better performance across all tasks (except numeric memory), while those endorsing a morning preference performed worse than the intermediate group. It must be noted that effect size differences for evening and morning chronotypes, relative to the intermediate group, were in the very small range (SD unit difference: 0.023–0.0116). This is the first time that such relationships have been observed in a large population-based sample with a standardized test battery, supporting a range of smaller studies reporting on academic achievement, salary and intelligence outcomes [39–42]. We note, however, that our findings are at odds with evidence from diffusion tensor imaging showing white matter deficits in frontal and temporal lobes, cingulate gyrus and corpus callosum in evening types [43]. Although we were unable to investigate the time of testing in relation to chronotype and performance, assessments were conducted during standard office hours and therefore would be expected to work against evening types, rather than account for superior performance. Findings are consistent with our recent biobank-GWAS, which found that genetic loci underlying evenness were associated with higher educational attainment [44]. Of note, we found that chronotype–performance associations were independent of educational background and socioeconomic status. Theoretical conceptualisations of an evening chronotype advantage and morning type impairment remain underdeveloped [45], but our work suggests that these are likely to be reliable associations at the population level.

We observed that sleep medication and long and short sleep durations were independently associated with poorer cognitive performance (SD unit difference: 0.048–0.132 [sleep medication], 0.013–0.069 [short sleep duration] and 0.094–0.269 [long sleep duration]). These effects have been shown across a range of study designs and samples [17,20,46,47], but our study is particularly noteworthy given our ability to partial out the effect of potential confounders, including both sleep and non-sleep variables. We could not record history or duration of sleep medication use, but both acute and chronic use of benzodiazepines and/or non-benzodiazepine receptor agonists is known to be associated with cognitive and psychomotor impairments [47], while their discontinuation in chronic users is associated with improved cognitive status [48]. Sleep medication use appears to be more robustly associated with cognitive impairment than insomnia symptoms, which may have important clinical implications. It of course remains possible that extremes of sleep duration and sleep medication use act as proxies for underlying poor health, accounting for associated impairment. Future, longitudinal efforts are needed to examine this possibility more directly, incorporating a greater.

### Table 3

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Multivariate-adjusted relationships between sleep-related variables (chronotype, sleep medication and sleep duration) and cognitive performance (model 4).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reasoning</td>
<td>Reaction time</td>
</tr>
<tr>
<td>(n = 115,668)</td>
<td>(n = 332,303)</td>
</tr>
<tr>
<td>Morning chronotypea</td>
<td>β = −2.5 × 10⁻¹</td>
</tr>
<tr>
<td>p &lt; 10⁻²²</td>
<td>p &lt; 10⁻¹³</td>
</tr>
<tr>
<td>Evening chronotypea</td>
<td>β = 1.4 × 10⁻¹</td>
</tr>
<tr>
<td>p &lt; 10⁻¹⁰</td>
<td>p &lt; 10⁻₆</td>
</tr>
<tr>
<td>Sleep medication (vs. none)</td>
<td>β = −2.9 × 10⁻¹</td>
</tr>
<tr>
<td>p &lt; 10⁻⁷</td>
<td>p &lt; 10⁻⁴</td>
</tr>
<tr>
<td>Sleep duration &lt;7 h</td>
<td>β = −1.5 × 10⁻¹</td>
</tr>
<tr>
<td>p &lt; 10⁻⁴</td>
<td>p &lt; 10⁻⁵</td>
</tr>
<tr>
<td>Sleep duration &gt;9 h</td>
<td>β = −6.4 × 10⁻¹</td>
</tr>
<tr>
<td>p &lt; 10⁻⁴⁻⁴</td>
<td>p &lt; 10⁻⁴</td>
</tr>
</tbody>
</table>

Adjusted for age, sex, socioeconomic status, education, BMI, hypertension, antihypertensive medication, cardiovascular disease, depressive symptoms, psychotropic medication and remaining sleep variables [sleep medication, chronotype, sleep duration and insomnia symptoms].

a Compared with intermediate chronotype (reference).
b Compared with 7–9 h of sleep duration (reference).
number of potential health-related confounds. Finally, an examination of associations between sleep traits and functional and structural neuroimaging parameters is now required to shed light on putative brain mechanisms underlying performance profiles.

4.2. Limitations

Our study has several important caveats. First, this was a cross-sectional study and therefore our findings cannot elucidate causality. Second, our cognitive dependent variables were created for brief completion on large numbers of participants and hence have not undergone formal validation. In partial mitigation, principal component analyses support an unexpected underlying performance (g) factor across tasks, and test-retest suggests good stability for most task-dependent variables [22]. Moreover, associations with variables in the expected direction (eg, with age and education), evidence of impairment in those with psychiatric disorder [24] and associations with several genetic variants [49] provide further support of task validity. However, tasks were brief and did not parametrically manipulate cognitive load, and the battery did not sample additional domains of cognition, potentially contributing to limited sensitivity for insomnia-related impairment. Third, our sleep trait predictor variables were limited by their low resolution, reflecting just single item self-report questions. For example, our sleep duration estimate included daytime naps and therefore we could not separate the contribution of night and daytime sleep, which may have affected group categorisation and, by extension, could not investigate subtypes of insomnia that may have unique relationships with cognitive impairment [16]. Specifically, we could not categorise participants into insomnia disorder because we lacked information on chronicity of sleep problems, quantitative criteria (eg, minutes for sleep-onset latency and wake-time during the night), attribution for daytime cognitive impairment or help-seeking. Greater precision around these factors and objective sleep data may have identified sub-groups of participants with cognitive impairment [12,15,18,30,50]. Our results therefore can only speak to frequent insomnia symptoms at the population level. Fourth, our sample age was restricted to those predominantly in the middle age. It may be that insomnia confers the greatest risk to cognitive impairment in elderly samples [23]. Fifth, while the UK Biobank represents a large and unique resource, the recruitment method and low response rate (5.5%) may have resulted in selection biases, potentially limiting generalisability to the broader UK population [51]. Sixth, sample size differed across statistical models owing to missing data for specific covariates of interest. However, we note that when analyses were restricted to complete data across all models, findings remain unchanged (see Supplementary Table 2). Finally, our analyses were based exclusively on Gaussian linear models, and we did not test whether nonlinear and/or non-Gaussian models would reveal more nuanced associations between our predictor and outcome variables.

4.3. Conclusion

In our large UK sample, frequent insomnia symptoms were not independently associated with cognitive impairment. Indeed, contrary to our hypotheses, we found a small statistical advantage for those with frequent insomnia symptoms over those without, which is unlikely to be clinically meaningful. Our data in no way undermine subjective daytime reports of those with poor sleep because task performance may not fully map onto daytime phenomenology [4,10]. We cannot exclude the possibility that those with insomnia disorder or discrete sub-groups of insomnia do not exhibit reliable performance impairment. Reliability of, and mechanisms underpinning, the small evening chronotype advantage and morning chronotype disadvantage requires further examination, including consideration of time of testing. Finally, our results corroborate the cognitive risks associated with sleep medication use and both long and short sleep durations.

Disclosure

All receives a salary from Big Health Ltd. CAE is a shareholder and co-founder of Big Health Ltd. MKR has received research support from GSK and Novo Nordisk, acted as a consultant for GSK, Roche and Cell Catapult, and is a stockholder in GSK. RS has received salary from and is a stockholder in Astrazeneca and Surface Oncology. SDK has previously acted as a consultant for Big Health Ltd. All remaining authors declare no potential conflicts of interest.

Acknowledgement

This research has been conducted using the UK Biobank Resource.

Conflict of interest

The ICMJE Uniform Disclosure Form for Potential Conflicts of Interest associated with this article can be viewed by clicking on the following link: http://dx.doi.org/10.1016/j.sleep.2017.07.001.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.sleep.2017.07.001.

References


